Overview

BGS649 Monotherapy in Moderate to Severe Endometriosis Patients

Status:
Completed
Trial end date:
2011-09-01
Target enrollment:
Participant gender:
Summary
This study will assess the safety and tolerability of BGS649 in women with moderate to severe endometriosis.
Phase:
Phase 2
Details
Lead Sponsor:
Mereo BioPharma
Novartis
Collaborator:
Novartis